35.69
0.71 (2.03%)
| Previous Close | 34.98 |
| Open | 35.00 |
| Volume | 690,693 |
| Avg. Volume (3M) | 808,190 |
| Market Cap | 3,351,280,128 |
| Price / Sales | 5.77 |
| Price / Book | 13.13 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2025 - 5 May 2025 |
| Profit Margin | -101.60% |
| Operating Margin (TTM) | -74.16% |
| Diluted EPS (TTM) | -6.29 |
| Quarterly Revenue Growth (YOY) | 29.40% |
| Total Debt/Equity (MRQ) | 346.94% |
| Current Ratio (MRQ) | 2.37 |
| Operating Cash Flow (TTM) | -414.19 M |
| Levered Free Cash Flow (TTM) | -207.49 M |
| Return on Assets (TTM) | -22.37% |
| Return on Equity (TTM) | -211.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ultragenyx Pharmaceutical Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.25 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 3.45% |
| % Held by Institutions | 97.24% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 136.00 (Canaccord Genuity, 281.06%) | Buy |
| Median | 117.00 (227.82%) | |
| Low | 95.00 (HC Wainwright & Co., 166.18%) | Buy |
| Average | 116.20 (225.58%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 41.48 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 27 Mar 2025 | 117.00 (227.82%) | Buy | 38.89 |
| Piper Sandler | 17 Mar 2025 | 115.00 (222.22%) | Buy | 39.64 |
| Cantor Fitzgerald | 26 Feb 2025 | 118.00 (230.62%) | Buy | 41.62 |
| Canaccord Genuity | 18 Feb 2025 | 136.00 (281.06%) | Buy | 43.62 |
| HC Wainwright & Co. | 18 Feb 2025 | 95.00 (166.18%) | Buy | 43.62 |
| 14 Feb 2025 | 95.00 (166.18%) | Buy | 42.49 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |